Gwen A Melincoff - Net Worth and Insider Trading

Gwen A Melincoff Net Worth

The estimated net worth of Gwen A Melincoff is at least $25,273 dollars as of 2024-04-28. Gwen A Melincoff is the Director of Soleno Therapeutics Inc and owns about 667 shares of Soleno Therapeutics Inc (SLNO) stock worth over $25,273. Details can be seen in Gwen A Melincoff's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Gwen A Melincoff has not made any transactions after 2019-11-19 and currently still holds the listed stock(s).

Transaction Summary of Gwen A Melincoff

To

Gwen A Melincoff Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gwen A Melincoff owns 5 companies in total, including Collegium Pharmaceutical Inc (COLL) , Soleno Therapeutics Inc (SLNO) , and Protalix BioTherapeutics Inc (PLX) among others .

Click here to see the complete history of Gwen A Melincoff’s form 4 insider trades.

Insider Ownership Summary of Gwen A Melincoff

Ticker Comapny Transaction Date Type of Owner
COLL Collegium Pharmaceutical Inc 2022-05-19 director
SLNO Soleno Therapeutics Inc 2019-11-19 director
PLX Protalix BioTherapeutics Inc 2020-01-01 director
RGDO Regado Biosciences Inc 2016-11-01 director
GANX Gain Therapeutics Inc 2021-03-17 director

Gwen A Melincoff Latest Holdings Summary

Gwen A Melincoff currently owns a total of 1 stock. Gwen A Melincoff owns 667 shares of Soleno Therapeutics Inc (SLNO) as of November 19, 2019, with a value of $25,273.

Latest Holdings of Gwen A Melincoff

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SLNO Soleno Therapeutics Inc 2019-11-19 667 37.89 25,273

Holding Weightings of Gwen A Melincoff


Gwen A Melincoff Form 4 Trading Tracker

According to the SEC Form 4 filings, Gwen A Melincoff has made a total of 1 transactions in Soleno Therapeutics Inc (SLNO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Soleno Therapeutics Inc is the acquisition of 667 shares on November 19, 2019, which cost Gwen A Melincoff around $15,400.

Insider Trading History of Gwen A Melincoff

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gwen A Melincoff Trading Performance

GuruFocus tracks the stock performance after each of Gwen A Melincoff's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Gwen A Melincoff is 121.71%. GuruFocus also compares Gwen A Melincoff's trading performance to market benchmark return within the same time period. The performance of stocks bought by Gwen A Melincoff within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Gwen A Melincoff's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Gwen A Melincoff

Average Return

32.79%

Average return per transaction

Outperforming Transactions

100%

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 12.5 121.71 150.66 32.79 -30.62 -63.05
Relative Return to S&P 500(%) 9.77 113.19 156.98 18.04 -53.29 -71.37

Gwen A Melincoff Ownership Network

Ownership Network List of Gwen A Melincoff

No Data

Ownership Network Relation of Gwen A Melincoff


Gwen A Melincoff Owned Company Details

What does Collegium Pharmaceutical Inc do?

Who are the key executives at Collegium Pharmaceutical Inc?

Gwen A Melincoff is the director of Collegium Pharmaceutical Inc. Other key executives at Collegium Pharmaceutical Inc include EVP & Chief Commercial Officer Scott Dreyer , director & President and CEO Joseph Ciaffoni , and EVP and General Counsel Shirley R. Kuhlmann .

Collegium Pharmaceutical Inc (COLL) Insider Trades Summary

Over the past 18 months, Gwen A Melincoff made no insider transaction in Collegium Pharmaceutical Inc (COLL). Other recent insider transactions involving Collegium Pharmaceutical Inc (COLL) include a net sale of 362,915 shares made by Joseph Ciaffoni , a net sale of 298,612 shares made by Michael Thomas Heffernan , and a net sale of 65,395 shares made by Shirley R. Kuhlmann .

In summary, during the past 3 months, insiders sold 10,000 shares of Collegium Pharmaceutical Inc (COLL) in total and bought 0 shares, with a net sale of 10,000 shares. During the past 18 months, 778,316 shares of Collegium Pharmaceutical Inc (COLL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 778,316 shares.

Collegium Pharmaceutical Inc (COLL)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Collegium Pharmaceutical Inc Insider Transactions

No Available Data

Gwen A Melincoff Mailing Address

Above is the net worth, insider trading, and ownership report for Gwen A Melincoff. You might contact Gwen A Melincoff via mailing address: C/o Tobira Therapeutics, Inc., 701 Gateway Boulevard, South San Francisco Ca 94080.

Discussions on Gwen A Melincoff

No discussions yet.